The initial success of Viagra undeniably reshaped the drug landscape, but investing in companies strongly reliant on off-patent versions presents a challenging picture. Although early profits were impressive, the expiration of patents and the appearance of cheaper alternatives have diminished market share. Therefore, a thorough assessment of presen